{
  "docId": "019de076-d25f-763f-9eab-9ec8cb3a6b5e",
  "docSlug": "0f1a880702ed9ddf7f6316bb24fc6717",
  "documentTitle": "Genelux | Investor Presentation Deck | 37 slides",
  "authorId": "genelux",
  "authorName": "Genelux",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 37,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "The slide outlines the trial parameters (n=27) and highlights the transition to the OnPrime Phase 3 trial.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-d25f-763f-9eab-9ec8cb3a6b5e/10",
  "deckHref": "/decks/019de076-d25f-763f-9eab-9ec8cb3a6b5e",
  "deckJsonHref": "/decks/019de076-d25f-763f-9eab-9ec8cb3a6b5e.json",
  "deckAnchorHref": "/decks/019de076-d25f-763f-9eab-9ec8cb3a6b5e#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.73,
        "y": 0.56
      },
      "kind": "callout",
      "text": "OnPrime Phase 3 Trial: Ongoing Pivotal Phase 3 for the treatment of PRROC patients, using the same Experimental Arm treatment regimen",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "280c5d9e-e45e-4414-bffa-fd8c2c4cd65a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.44,
        "x": 0.28,
        "y": 0.29
      },
      "kind": "diagram",
      "text": "Interventional Single Group Assignment n=27. Design: Olvi-Vec via intraperitoneal infusion. Endpoints: Primary (mPFS, ORR, CA-125), Secondary (mOS).",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "63d91b4a-c8ef-43ff-8d49-aa7eb42070f9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.02,
        "y": 0.29
      },
      "kind": "list",
      "text": "Key Inclusion Criteria: High-grade serous, endometrioid or clear-cell ovarian cancer; platinum-resistant or PRROC with at least two prior lines of therapy; ECOG Performance status 0 or 1",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "718d78c4-4fd2-4ab7-adb4-055b60d6b945",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.73,
        "y": 0.25
      },
      "kind": "list",
      "text": "Data Presentations: 1. 2020 Digital Annual Meeting of International Gynecologic Cancer Society (Oral Plenary Session). 2. JAMA Oncology (Selected for Journal podcast series interview).",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1ceb7e57-95ee-4a2d-9ab9-6fb29e4af473",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.35,
        "y": 0.79
      },
      "kind": "paragraph",
      "text": "Results of the VIRO-15 Phase 2 Trial were published in JAMA Oncology (Link)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0bb69d15-9d15-4d5c-b4f5-f568595db013",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.1,
        "y": 0.12
      },
      "kind": "title",
      "text": "Heavily Pretreated Patients with Platinum-Resistant or Platinum-Refractory Ovarian Cancer",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "315085bf-8d62-4665-8213-da6b49330027",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Completed Phase 2 Tested Olvi-Vec-primed Immunochemotherapy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "100322c8-9c6a-4da9-b431-b9c58790e98a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "SCQA Framework",
      "slug": "scqa-framework",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "7ee951da-4dad-44d0-9951-d905385cd5ed",
      "evidence": "The slide contains a clear Situation, Complication, Question, and Answer (SCQA) framework in its components.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}